Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Not quite pharmacogenomics

Nature Biotechnology volume 16, page 1295 (1998)Cite this article

To the editor:

Your editorial "Pharmacogenomics at work" (Nature Biotechnology 16:885, October 1998) is off base. The use of a diagnostic test that detects overexpression of the HER2 antigen to identify breast cancer patients likely to benefit from Herceptin is not an example of pharmacogenomics.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Chairman and CEO Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, 20850, MD

    William A. Haseltine

Authors
  1. William A. Haseltine
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haseltine, W. Not quite pharmacogenomics. Nat Biotechnol 16, 1295 (1998). https://doi.org/10.1038/4244

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/4244

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing